Compound X restores mobility in Parkinson's mouse model
Why it matters: 80% of Parkinson‑model mice regained mobility, indicating a promising disease‑modifying approach for patients.
- Compound X – an FDA‑approved drug that enhances slow brainwaves and glymphatic clearance, was administered to Parkinson‑model mice four times weekly.
- Swinburne University – led by Zhao Yan, reported that 80% of treated mice completed a pole‑test versus only 10% of controls, showing dramatic functional recovery.
- Oxford Glymphatic and Brain Clearance Symposium – where the team presented the results, underscoring the potential of targeting the glymphatic system for disease‑modifying Parkinson’s treatments.
An FDA‑approved drug, dubbed compound X, boosted the brain’s waste‑clearance system and restored mobility in 80% of Parkinson‑like mice, hinting at a first disease‑modifying therapy for Parkinson’s disease.
